查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1387433

帕金森氏症市場報告：2030 年趨勢、預測和競爭分析

Parkinson Disease Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

帕金森氏症的趨勢和預測

預計到 2030 年，全球帕金森氏症市場將達到 88 億美元，2024 年至 2030 年年複合成長率為 6.1%。該市場的主要驅動力是高齡化的加劇、診斷技術的進步以及新興國家醫療保健支出的增加。全球帕金森氏症市場未來性廣闊，碳度巴/左旋多巴、多巴胺促效劑、MAO-B抑制劑、COMT抑制劑、抗膽鹼能藥物市場蘊藏商機。

帕金森氏症市場洞察

Lucintel 預計，由於易於獲取，零售藥局在預測期內仍將是最大的細分市場。

由於北美地區參與者眾多、可支配所得高、醫療成本高以及該地區完善的醫療保健系統，因此在預測期內，北美將繼續成為最大的地區。

本報告回答了 11 個關鍵問題：

  • Q.1. 細分市場中最有前途和高成長的機會是什麼？
  • Q.2. 未來哪個細分市場成長較快？為什麼？
  • Q.3.您認為哪些地區未來會出現更快的成長？為什麼？
  • Q.4. 影響市場動態的主要因素有哪些？市場的主要挑戰和商業風險是什麼？
  • Q.5. 這個市場的商業風險和競爭威脅是什麼？
  • Q.6.這個市場有哪些新趨勢？為什麼？
  • Q.7.市場客戶需求有何改變？
  • Q.8. 該市場有哪些新發展以及哪些公司處於領先地位？
  • Q.9.這個市場的主要企業有哪些？主要企業採取哪些策略配合措施來發展業務？
  • Q.10. 該市場上的競爭產品有哪些？由於材料或產品替代而導致市場佔有率下降的威脅有多大？
  • Q.11.過去年度發生了哪些併購事件，對產業產生了哪些影響？

目錄

第1章 執行摘要

第2章 全球帕金森氏症市場：市場動態

  • 簡介、背景、分類
  • 供應鏈
  • 產業促進因素與挑戰

第3章 2018-2030年市場趨勢及預測分析

  • 宏觀經濟趨勢（2018-2023）與預測（2024-2030）
  • 全球帕金森氏症市場趨勢（2018-2023）與預測（2024-2030）
  • 按藥物類別分類的全球帕金森氏症市場
    • Carbidopa-Levodopa
    • 多巴胺促效劑
    • MAO-B抑制劑
    • COMT抑制劑
    • 抗膽鹼能藥物
    • 其他
  • 按配銷通路分類的全球帕金森氏症市場
    • 醫院藥房
    • 零售藥房
    • 線上藥房

第4章 2018-2030年分地區市場趨勢及預測分析

  • 全球帕金森氏症市場區域分佈
  • 北美帕金森氏症市場
  • 歐洲帕金森氏症市場
  • 亞太帕金森氏症市場
  • 其他區域帕金森氏症市場

第5章 競爭分析

  • 產品系列分析
  • 營運整合
  • 波特五力分析

第6章 成長機會與策略分析

  • 成長機會分析
    • 按藥物類別分類的全球帕金森氏症市場成長機會
    • 全球帕金森氏症市場成長機會（按配銷通路）
    • 全球帕金森氏症市場成長機會（按地區）
  • 全球帕金森氏症市場的新興趨勢
  • 戰略分析
    • 新產品開發
    • 擴大全球帕金森氏症市場的產能
    • 全球帕金森氏症市場的合併、收購和合資企業
    • 認證和許可

第7章 主要企業概況

  • Cerevel Therapeutics
  • Novartis
  • Teva Pharmaceutical Industries
  • Merck & Co.
  • GlaxoSmithKline
  • AbbVie
  • H. Lundbeck
簡介目錄

Parkinson Disease Trends and Forecast

The future of the global parkinson disease market looks promising with opportunities in the carbidopa-levodopa, dopamine agonists, MAO-B inhibitors, COMT inhibitors, and anticholinergics markets. The global parkinson disease market is expected to reach an estimated $8.8 billion by 2030 with a CAGR of 6.1% from 2024 to 2030. The major drivers for this market are rising aging population, advances in diagnostic technologies, and increasing healthcare expenditure in emerging economies.

A more than 150-page report is developed to help in your business decisions.

Parkinson Disease by Segment

The study includes a forecast for the global parkinson disease by drug class, distribution channel, and region.

Parkinson Disease Market by Drug Class [Shipment Analysis by Value from 2018 to 2030]:

  • Carbidopa-Levodopa
  • Dopamine Agonists
  • Mao-B Inhibitors
  • Comt Inhibitors
  • Anticholinergics
  • Others

Parkinson Disease Market by Distribution Channel [Shipment Analysis by Value from 2018 to 2030]:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Parkinson Disease Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Parkinson Disease Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies parkinson disease companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the parkinson disease companies profiled in this report include-

  • Cerevel Therapeutics
  • Novartis
  • Teva Pharmaceutical Industries
  • Merck & Co.
  • GlaxoSmithKline
  • AbbVie
  • H. Lundbeck

Parkinson Disease Market Insights

Lucintel forecasts that retail pharmacy will remain the largest segment over the forecast period due to ease of availbility.

North America will remain the largest region over the forecast period due to large number of important participants, high disposable income, high costs for healthcare, and an established healthcare system in this area.

Features of the Global Parkinson Disease Market

Market Size Estimates: Parkinson disease market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Parkinson disease market size by drug class, distribution channel, and region in terms of value ($B).

Regional Analysis: Parkinson disease market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different drug class, distribution channel, and regions for the parkinson disease market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the parkinson disease market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the parkinson disease market size?

Answer: The global parkinson disease market is expected to reach an estimated $8.8 billion by 2030.

Q2. What is the growth forecast for parkinson disease market?

Answer: The global parkinson disease market is expected to grow with a CAGR of 6.1% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the parkinson disease market?

Answer: The major drivers for this market are rising aging population, advances in diagnostic technologies, and increasing healthcare expenditure in emerging economies.

Q4. What are the major segments for parkinson disease market?

Answer: The future of the global parkinson disease market looks promising with opportunities in the carbidopa-levodopa, dopamine agonists, MAO-B inhibitors, COMT inhibitors, and anticholinergics markets.

Q5. Who are the key parkinson disease market companies?

Answer: Some of the key parkinson disease companies are as follows:

  • Cerevel Therapeutics
  • Novartis
  • Teva Pharmaceutical Industries
  • Merck & Co.
  • GlaxoSmithKline
  • AbbVie
  • H. Lundbeck

Q6. Which parkinson disease market segment will be the largest in future?

Answer: Lucintel forecasts that retail pharmacy will remain the largest segment over the forecast period due to ease of availbility.

Q7. In parkinson disease market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to large number of important participants, high disposable income, high costs for healthcare, and an established healthcare system in this area.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the parkinson disease market by drug class (carbidopa-levodopa, dopamine agonists, MAO-B inhibitors, COMT inhibitors, anticholinergics, and others), distribution channel (hospital pharmacy, retail pharmacy, and online pharmacy), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Parkinson Disease Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Parkinson Disease Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Parkinson Disease Market by Drug Class
    • 3.3.1: Carbidopa-Levodopa
    • 3.3.2: Dopamine Agonists
    • 3.3.3: MAO-B Inhibitors
    • 3.3.4: COMT Inhibitors
    • 3.3.5: Anticholinergics
    • 3.3.6: Others
  • 3.4: Global Parkinson Disease Market by Distribution Channel
    • 3.4.1: Hospital Pharmacy
    • 3.4.2: Retail Pharmacy
    • 3.4.3: Online Pharmacy

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Parkinson Disease Market by Region
  • 4.2: North American Parkinson Disease Market
    • 4.2.2: North American Parkinson Disease Market by Distribution Channel: Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy
  • 4.3: European Parkinson Disease Market
    • 4.3.1: European Parkinson Disease Market by Drug Class: Carbidopa-Levodopa, Dopamine Agonists, MAO-B Inhibitors, COMT Inhibitors, Anticholinergics, and Others
    • 4.3.2: European Parkinson Disease Market by Distribution Channel: Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy
  • 4.4: APAC Parkinson Disease Market
    • 4.4.1: APAC Parkinson Disease Market by Drug Class: Carbidopa-Levodopa, Dopamine Agonists, MAO-B Inhibitors, COMT Inhibitors, Anticholinergics, and Others
    • 4.4.2: APAC Parkinson Disease Market by Distribution Channel: Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy
  • 4.5: ROW Parkinson Disease Market
    • 4.5.1: ROW Parkinson Disease Market by Drug Class: Carbidopa-Levodopa, Dopamine Agonists, MAO-B Inhibitors, COMT Inhibitors, Anticholinergics, and Others
    • 4.5.2: ROW Parkinson Disease Market by Distribution Channel: Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Parkinson Disease Market by Drug Class
    • 6.1.2: Growth Opportunities for the Global Parkinson Disease Market by Distribution Channel
    • 6.1.3: Growth Opportunities for the Global Parkinson Disease Market by Region
  • 6.2: Emerging Trends in the Global Parkinson Disease Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Parkinson Disease Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Parkinson Disease Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Cerevel Therapeutics
  • 7.2: Novartis
  • 7.3: Teva Pharmaceutical Industries
  • 7.4: Merck & Co.
  • 7.5: GlaxoSmithKline
  • 7.6: AbbVie
  • 7.7: H. Lundbeck